Streamlining clinical trials
By Michel Goossens
Every day, the internet is used to perform countless transactions. While the internet may seem limitless, the technology, itself, is flawed in that it is not capable of assigning actual ownership of the transacted item, or asset. As a result, we assign intermediaries that can do the ownership accounting for us, such as the bank or website used to perform the transaction. Unfortunately, the use of intermediaries can limit transactions, making them both inefficient and costly. Therefore, a new technology has emerged called blockchain, which has streamlined asset exchange by allowing transactions to occur without this intermediary. Additionally, blockchain creates a public record of transacted items between parties.
The beauty of blockchain is that the digital ledger can be programmed to record not just financial transactions, but also virtually everything of value, including information. Thus, the tech community is beginning to uncover other potential uses for the technology (beyond its claim to fame, the bitcoin), which increasingly includes applications in the healthcare and clinical trial spaces.
Opportunity for blockchain in healthcare and clinical trials
Within the healthcare and clinical trial space, patient data is the most notable item of transactional nature between networks such as healthcare institutions, patients, and regulators. Because blockchain ledgers allow for user confidentiality, patient privacy can be protected during exchange of data between parties. This means that two healthcare institutions can add or access information kept on a blockchain for a single patient without breaching the patient’s privacy. Then, other users within the network also can access this information, such as insurance companies and CROs.
Additionally, blockchain technology allows for complete transparency of data, which has immense potential within clinical trials. Given the impact of products entering the healthcare space, it is important that there is trust in the way that data is produced, transmitted and altered. With blockchain, there is an audit trail built into transaction of data, which allows for verification of the original source of the information being transacted, as well as the ability to detect any attempts to tamper with it.
Finally, blockchain allows for greater data availability. When all data is shared openly within a network, issues with data systems interoperability are reduced, and opportunities open up new possibilities for using that data. For example, in the clinical trial space, availability and accessibility of patient information could be used for patient feasibility analysis and population studies.
Applications in development
Clinical trial efficiency, cost and transparency are some of the biggest challenges in drug and device development, making blockchain a game-changer for streamlining these processes. Thus, there are a number of organisations working towards the development of blockchain in the healthcare and clinical trial space:
- In 2016, physicians Greg Irving and John Holden from the University of Cambridge performed a proof of concept study utilising blockchain technology. The aim of their study was to increase the trustworthiness of clinical trial results by using blockchain to prevent the selective publication and manipulation of data (1).
- Professor Antonia Bifulco, in collaboration from Middlesex University, King’s College London and Goldsmiths University in the UK (2,3), developed a new online Computerised Life Event Assessment Record (CLEAR) for a trial measuring stress related to life changes. The project utilised a blockchain to store all trial results on a ledger, which allows for the data to be easily distributed for review and auditing
Navigating digital disruption
Integrating new technologies such as blockchain and other emerging technologies (i.e. machine learning) is a key component to increasing efficiency in clinical trials. However, a significant amount of expertise is required to successfully employ these digitally disruptive innovations into your study. ICON is an experienced partner in digital disruption who can help you navigate the nuances of emerging technologies such as blockchain.
What is Blockchain?
How may this innovation translate to the clinical research industry?
Sources
- Greg Irving 1, John Holden 2, How blockchain-timestamped protocols could improve the trustworthiness of medical science, Retracted article; https://f1000research.com/articles/5-222/v3, but media published: https://www.economist.com/news/science-and-technology/21699099-blockchain-technology-could-improve-reliability-medical-trials-better
(no listed author), Clinical Trial Records Move To Blockchain, March 23, 2016
3. CLEAR Project website
In this section
-
Digital Disruption
-
Digital Disruption whitepaper
- AI and clinical trials
-
Clinical trial data anonymisation and data sharing
-
Clinical Trial Tokenisation
-
Closing the evidence gap: The value of digital health technologies in supporting drug reimbursement decisions
-
Digital disruption in biopharma
-
Disruptive Innovation
- Remote Patient Monitoring
-
Personalising Digital Health
- Real World Data
-
The triad of trust: Navigating real-world healthcare data integration
-
Digital Disruption whitepaper
-
Patient Centricity
-
Agile Clinical Monitoring
-
Capturing the voice of the patient in clinical trials
-
Charting the Managed Access Program Landscape
-
Developing Nurse-Centric Medical Communications
- Diversity and inclusion in clinical trials
-
Exploring the patient perspective from different angles
-
Patient safety and pharmacovigilance
-
A guide to safety data migrations
-
Taking safety reporting to the next level with automation
-
Outsourced Pharmacovigilance Affiliate Solution
-
The evolution of the Pharmacovigilance System Master File: Benefits, challenges, and opportunities
-
Sponsor and CRO pharmacovigilance and safety alliances
-
Understanding the Periodic Benefit-Risk Evaluation Report
-
A guide to safety data migrations
-
Patient voice survey
-
Patient Voice Survey - Decentralised and Hybrid Trials
-
Reimagining Patient-Centricity with the Internet of Medical Things (IoMT)
-
Using longitudinal qualitative research to capture the patient voice
-
Agile Clinical Monitoring
-
Regulatory Intelligence
-
An innovative approach to rare disease clinical development
- EU Clinical Trials Regulation
-
Using innovative tools and lean writing processes to accelerate regulatory document writing
-
Current overview of data sharing within clinical trial transparency
-
Global Agency Meetings: A collaborative approach to drug development
-
Keeping the end in mind: key considerations for creating plain language summaries
-
Navigating orphan drug development from early phase to marketing authorisation
-
Procedural and regulatory know-how for China biotechs in the EU
-
RACE for Children Act
-
Early engagement and regulatory considerations for biotech
-
Regulatory Intelligence Newsletter
-
Requirements & strategy considerations within clinical trial transparency
-
Spotlight on regulatory reforms in China
-
Demystifying EU CTR, MDR and IVDR
-
Transfer of marketing authorisation
-
An innovative approach to rare disease clinical development
-
Therapeutics insights
- Endocrine and Metabolic Disorders
- Cardiovascular
- Cell and Gene Therapies
- Central Nervous System
-
Glycomics
- Infectious Diseases
- NASH
- Oncology
- Paediatrics
-
Respiratory
-
Rare and orphan diseases
-
Advanced therapies for rare diseases
-
Cross-border enrollment of rare disease patients
-
Crossing the finish line: Why effective participation support strategy is critical to trial efficiency and success in rare diseases
-
Diversity, equity and inclusion in rare disease clinical trials
-
Identify and mitigate risks to rare disease clinical programmes
-
Leveraging historical data for use in rare disease trials
-
Natural history studies to improve drug development in rare diseases
-
Patient Centricity in Orphan Drug Development
-
The key to remarkable rare disease registries
-
Therapeutic spotlight: Precision medicine considerations in rare diseases
-
Advanced therapies for rare diseases
-
Transforming Trials
-
Accelerating biotech innovation from discovery to commercialisation
-
Ensuring the validity of clinical outcomes assessment (COA) data: The value of rater training
-
Linguistic validation of Clinical Outcomes Assessments
-
Optimising biotech funding
- Adaptive clinical trials
-
Best practices to increase engagement with medical and scientific poster content
-
Decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
Decentralised and Hybrid clinical trials
-
Practical considerations in transitioning to hybrid or decentralised clinical trials
-
Navigating the regulatory labyrinth of technology in decentralised clinical trials
-
Biopharma perspective: the promise of decentralised models and diversity in clinical trials
-
eCOA implementation
- Blended solutions insights
-
Implications of COVID-19 on statistical design and analyses of clinical studies
-
Improving pharma R&D efficiency
-
Increasing Complexity and Declining ROI in Drug Development
-
Innovation in Clinical Trial Methodologies
- Partnership insights
-
Risk Based Quality Management
-
Transforming the R&D Model to Sustain Growth
-
Accelerating biotech innovation from discovery to commercialisation
-
Value Based Healthcare
-
Strategies for commercialising oncology treatments for young adults
-
US payers and PROs
-
Accelerated early clinical manufacturing
-
Cardiovascular Medical Devices
-
CMS Part D Price Negotiations: Is your drug on the list?
-
COVID-19 navigating global market access
-
Ensuring scientific rigor in external control arms
-
Evidence Synthesis: A solution to sparse evidence, heterogeneous studies, and disconnected networks
-
Global Outcomes Benchmarking
-
Health technology assessment
-
Perspectives from US payers
-
ICER’s impact on payer decision making
-
Making Sense of the Biosimilars Market
-
Medical communications in early phase product development
-
Navigating the Challenges and Opportunities of Value Based Healthcare
-
Payer Reliance on ICER and Perceptions on Value Based Pricing
-
Payers Perspectives on Digital Therapeutics
-
Precision Medicine
-
RWE Generation Cross Sectional Studies and Medical Chart Review
-
Survey results: How to engage healthcare decision-makers
-
The affordability hurdle for gene therapies
-
The Role of ICER as an HTA Organisation
-
Strategies for commercialising oncology treatments for young adults
-
Blog
-
Videos
-
Webinar Channel